Immunai Signs Agreement with Bristol Myers Squibb to Advance Clinical Development Through Immune System Intelligence

The agreement will leverage Immunai’s AMICA-OS™, its AI operating system, to generate deep, immune-centric insights that support clinical development programs.

Immunai, a leading AI biotech company specializing in mapping the human immune system, today announced it has signed an agreement with Bristol Myers Squibb (BMS). Under the agreement, Immunai will analyze data to support BMS’s clinical development efforts by applying its AI-powered operating system, AMICA-OS™, to gain deeper insight into patient immune responses and inform clinical decision-making.

These  analyses will leverage Immunai’s immune system AI models and infrastructure within AMICA-OS™ to analyze high-dimensional immune data from clinical studies. The goal is to improve understanding of patient biology and variability in response to therapy, supporting key clinical development activities including immune-driven mechanisms of action, patient stratification, biomarker discovery, and data-informed decision-making.

“Understanding the immune system at the level required to guide clinical development remains one of the most complex challenges in drug development,” said Noam Solomon, Ph.D., CEO of Immunai. “Through our work with Bristol Myers Squibb, we will apply AMICA-OS™ to translate complex immune data into actionable insights that can support clinical decision-making and may ultimately help advance better therapies for patients.”

“At Bristol Myers Squibb, we are focused on leveraging innovative approaches that deepen our understanding of patient biology and treatment response,” said Bryan Campbell, Senior Vice President, Head of Drug Development Strategy and Innovation at Bristol Myers Squibb. “Our work with Immunai will enable the use of advanced AI technologies to generate meaningful immune insights from clinical data, supporting our efforts to advance the development of transformative medicines.”

If successful, this work has the potential to expand across additional programs as the companies continue to explore the application of Immunai’s AMICA-OS™ to support immune-driven clinical development.

Immunai uses single-cell genomics and machine learning to decode the human immune system and improve the development of novel therapeutics. The company’s AMICA-OS™ AI operating system integrates large-scale immune data with foundation models to generate mechanistic and clinically relevant insights. With a team of over 190 experts, the company collaborates with leading pharmaceutical firms and academic institutions. Immunai is headquartered in New York City and has raised close to $270 million in funding to date.

Credit: Gil Kovalchuk